Head-To-Head Comparison: Boston Scientific Corporation (BSX) versus Its Competitors

Boston Scientific Corporation (NYSE: BSX) is one of 87 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its peers? We will compare Boston Scientific Corporation to similar businesses based on the strength of its analyst recommendations, valuation, earnings, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Boston Scientific Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Boston Scientific Corporation 9.55% 23.60% 9.24%
Boston Scientific Corporation Competitors -299.57% -36.17% -12.71%

Earnings and Valuation

This table compares Boston Scientific Corporation and its peers gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Boston Scientific Corporation $8.39 billion $347.00 million 45.67
Boston Scientific Corporation Competitors $2.13 billion $221.25 million 1.97

Boston Scientific Corporation has higher revenue and earnings than its peers. Boston Scientific Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Boston Scientific Corporation has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Boston Scientific Corporation’s peers have a beta of 1.26, meaning that their average stock price is 26% more volatile than the S&P 500.

Insider and Institutional Ownership

90.5% of Boston Scientific Corporation shares are owned by institutional investors. Comparatively, 51.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 0.7% of Boston Scientific Corporation shares are owned by company insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Boston Scientific Corporation and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific Corporation 0 4 13 0 2.76
Boston Scientific Corporation Competitors 267 1867 3359 108 2.59

Boston Scientific Corporation presently has a consensus target price of $31.11, suggesting a potential upside of 11.66%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 10.86%. Given Boston Scientific Corporation’s stronger consensus rating and higher possible upside, equities analysts clearly believe Boston Scientific Corporation is more favorable than its peers.

Summary

Boston Scientific Corporation beats its peers on 10 of the 13 factors compared.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit